ENABLE—App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial
ENABLE — App-basierte digitale Erfassung und Intervention von patientenberichteter Lebensqualität, unerwünschten Ereignissen und Behandlungssatistion bei Brustkrebs: Protokoll einer randomisierten kontrollierten Studie
JMIR Research Protocols · 26.05.2025 · 14 · e69855
DOI: 10.2196/69855 ↗Auf einen Blick
Die ENABLE-Studie erfasste bei Brustkrebs per Smartphone-App HRQoL, unerwünschte Ereignisse und Zufriedenheit. Die Intervention sollte individuelle Rückmeldungen geben und Unterstützung anbieten.
Fragestellung
Verbessert eine patientenberichtete, app-basierte Intervention die umfassende onkologische Versorgung von Patient:innen mit Brustkrebs?
Methode
Randomisierte kontrollierte Studie mit 1:1-Zuteilung; Rekrutierung in Heidelberg, Mannheim und Tübingen vor neoadjuvanter, adjuvanter, postneoadjuvanter oder palliativer Systemtherapie; Follow-up bis Februar 2024.
Ergebnisse
606 Patient:innen wurden eingeschlossen, 592 nahmen teil. In der Interventionsgruppe wurden HRQoL und bei Verschlechterung unerwünschte Ereignisse gestuft erfasst; Kontrollgruppe ohne diese Zusatzintervention.
Schlussfolgerung der Autor:innen
Die Autor:innen erwarten, dass die Intervention Behandlungssatistion, Adhärenz sowie Erkennung und rechtzeitige Behandlung kritischer unerwünschter Ereignisse verbessert.
Kernaussagen
- Smartphone-App zur Erfassung von HRQoL, AEs und Zufriedenheit
- 1:1-Randomisierung in Intervention und Kontrolle
- Erste Ergebnisse wurden für Q2 2025 erwartet
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, online erschienen am 26.05.2025. Verfasst von Thomas M Deutsch und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Quality of Life, Patient Satisfaction, Mobile Applications. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
In recent years, breast cancer treatment has taken the path toward personalized medicine. Based on individual tumor biology, therapy tailored to the particular subtype of cancer is increasingly being used. The aim here is to find the most suitable therapy for the disease. However, the success of therapy depends to a large extent on the patient’s adherence to treatment. This, in turn, depends on how the therapy is tolerated and how the treatment team cares for the patient. Patient-centered care seeks to identify and address the individual needs of each patient and to find the best form of care for that person.
Objective
In order to improve comprehensive oncological care of patients with breast cancer, the ENABLE trial digitally recorded the health-related quality of life (HRQoL), adverse events (AEs), and patient satisfaction using a mobile smartphone app. The trial provided individualized responses to reported AEs and offered assistance. Additionally, it assessed the impact of a patient-reported outcome–based intervention across various therapy settings.
Methods
Patients with breast cancer were eligible to participate in the study before neoadjuvant, adjuvant, postneoadjuvant, or palliative systemic therapy against breast cancer was initiated at the Heidelberg, Mannheim, and Tuebingen, Germany, university hospitals. After 1:1 randomization into an intervention and a control group, HRQoL assessments were performed at six fixed time points during the therapy using validated questionnaires. In the intervention group, HRQoL was also assessed briefly every week using a visual analog scale (EQ-VAS). In cases of significant deterioration, therapy-associated side effects were assessed in a graduated manner, recommendations were sent to the patient, and the treatment team was informed. Additionally, the app served as an “eHealth companion” for education, training, and organizational support during therapy.
Results
Recruitment started in March 2021; follow-up was completed in February 2024. In total, 606 patients were enrolled, and 592 patients participated in the study. Enrollment was completed in September 2023, and the last visit was in February 2024. The first results are expected to be published in Q2 2025.
Conclusions
Participation in the intervention group is expected to improve treatment satisfaction, adherence, detection, and timely treatment of critical AEs. The close-meshed, weekly, brief HRQoL assessment will also be tested as a screening tool to detect relevant side effects during therapy. The study offers a more objective HRQoL assessment across treatment strategies. Trial Registration Deutsches Register Klinischer Studien DRKS00025611; https://drks.de/search/en/trial/DRKS00025611 International Registered Report Identifier (IRRID) DERR1-10.2196/69855
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Gynecology and Obstetrics, University Hospital Tuebingen, Tuebingen, Germany.
- Institute of Medical Biometry, Heidelberg University, Heidelberg, Germany.
- Department of Gynecology and Obstetrics, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
- Institute Women's Health, Tuebingen, Germany.
- Institute of Medical Informatics, Heidelberg University, Heidelberg, Germany
ORCID-Profile: Thomas M Deutsch, Léa L Volmer, Manuel Feisst, Laura Bodenbeck, Kathrin Hassdenteufel, Lara Tretschock, Christiane Breit, Stefan Stefanovic, Armin Bauer, Carolin Anders, Lina Weinert, Tobias Engler, Andreas D Hartkopf, Nico Pfeifer, Pascal Escher, Marc Mausch, Oliver Heinze, Marc Suetterlin, Sara Y Brucker, Andreas Schneeweiss, Markus Wallwiener
Zitieren
APA
Deutsch, T. M., Volmer, L. L., Feisst, M., Bodenbeck, L., Hassdenteufel, K., Tretschock, L., Breit, C., Stefanovic, S., Bauer, A., Anders, C., Weinert, L., Engler, T., Hartkopf, A. D., Pfeifer, N., Escher, P., Mausch, M., Heinze, O., Suetterlin, M., Brucker, S. Y., …, & Wallwiener, M. (2025). ENABLE—App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 14, e69855. https://doi.org/10.2196/69855
Vancouver
Deutsch TM, Volmer LL, Feisst M, Bodenbeck L, Hassdenteufel K, Tretschock L, et al. ENABLE—App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial. JMIR Research Protocols. 2025;14:e69855. doi:10.2196/69855
BibTeX
@article{Deutsch2025,
author = {Deutsch, Thomas M and Volmer, Léa L and Feisst, Manuel and Bodenbeck, Laura and Hassdenteufel, Kathrin and Tretschock, Lara and Breit, Christiane and Stefanovic, Stefan and Bauer, Armin and Anders, Carolin and Weinert, Lina and Engler, Tobias and Hartkopf, Andreas D and Pfeifer, Nico and Escher, Pascal and Mausch, Marc and Heinze, Oliver and Suetterlin, Marc and Brucker, Sara Y and Schneeweiss, Andreas and Wallwiener, Markus},
title = {ENABLE—App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial},
journal = {JMIR Research Protocols},
year = {2025},
volume = {14},
pages = {e69855},
doi = {10.2196/69855}
}
EUVIMED